3-(5-bromo-2-methoxy-phenyl)-6-chloro-1H-pyrazolo[3,4-b]pyrazine | 872513-31-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(5-bromo-2-methoxy-phenyl)-6-chloro-1H-pyrazolo[3,4-b]pyrazine
• 英文别名: 3-(5-bromo-2-methoxyphenyl)-6-chloro-2H-pyrazolo[3,4-b]pyrazine
• CAS: 872513-31-0
• 化学式: C₁₂H₈BrClN₄O
• 分子量: 339.579
• InChiKey: CECJRJBZUVFVRJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  63.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(5-bromo-2-methoxy-phenyl)-6-chloro-1H-pyrazolo[3,4-b]pyrazine 在 palladium diacetate 、 palladium on activated charcoal copper(l) iodide 、 氢气 、 (R)-2,2'-bis(diphenylphosphanyl)-1,1'-binaphthyl 、 sodium t-butanolate 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 {3-[5-(3-Amino-3-methyl-butyl)-2-methoxy-phenyl]-1H-pyrazolo[3,4-b]pyrazin-6-yl}-(2,4-difluoro-phenyl)-amine
  参考文献：
  名称：

  Pyrazoloheteroaryls: Novel p38α MAP kinase inhibiting scaffolds with oral activity

  摘要：

  A test library with three novel p38 alpha inhibitory scaffolds and a narrow set of substituents was prepared. Appropriate combination of substituent and scaffold generated potent p38 alpha inhibitors, for example, pyrazolo[3,4-b]pyridine 9, pyrazolo[3,4-d]pyrimidine 18a and pyrazolo[3,4-b]pyrazine 23b with potent in vivo activity upon oral administration in animal models of rheumatoid arthritis. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.10.015
• 作为产物：
  描述：

  (5-bromo-2-methoxy-phenyl)-(2,4-dichloro-pyrimidin-5-yl)-methanone 在 一水合肼 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以36%的产率得到3-(5-bromo-2-methoxy-phenyl)-6-chloro-1H-pyrazolo[3,4-b]pyrazine
  参考文献：
  名称：

  Pyrazoloheteroaryls: Novel p38α MAP kinase inhibiting scaffolds with oral activity

  摘要：

  A test library with three novel p38 alpha inhibitory scaffolds and a narrow set of substituents was prepared. Appropriate combination of substituent and scaffold generated potent p38 alpha inhibitors, for example, pyrazolo[3,4-b]pyridine 9, pyrazolo[3,4-d]pyrimidine 18a and pyrazolo[3,4-b]pyrazine 23b with potent in vivo activity upon oral administration in animal models of rheumatoid arthritis. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.10.015

文献信息

• PYRAZOLO-HETEROARYL COMPOUNDS
  申请人：Revesz Lászlo

  公开号：US20090258874A1

  公开（公告）日：2009-10-15

  A compound of formula I wherein the groups R1-R4, X and Y are as defined in the specification, useful to treat TNF-Alpha and IL-1 mediated diseases.

  化合物I的公式为其中R1-R4，X和Y的基团如规范中所定义，可用于治疗TNF-Alpha和IL-1介导的疾病。
• WO2006/63820
  申请人：——

  公开号：——

  公开（公告）日：——
• Pyrazoloheteroaryls: Novel p38α MAP kinase inhibiting scaffolds with oral activity
  作者：Laszlo Revesz、Ernst Blum、Franco E. Di Padova、Thomas Buhl、Roland Feifel、Hermann Gram、Peter Hiestand、Ute Manning、Ulf Neumann、Gerard Rucklin

  DOI：10.1016/j.bmcl.2005.10.015

  日期：2006.1

  A test library with three novel p38 alpha inhibitory scaffolds and a narrow set of substituents was prepared. Appropriate combination of substituent and scaffold generated potent p38 alpha inhibitors, for example, pyrazolo[3,4-b]pyridine 9, pyrazolo[3,4-d]pyrimidine 18a and pyrazolo[3,4-b]pyrazine 23b with potent in vivo activity upon oral administration in animal models of rheumatoid arthritis. (c) 2005 Elsevier Ltd. All rights reserved.